首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1812408

細胞免疫療法市場按治療類型、來源、適應症、製造方式、最終用戶和地區分類

Cellular Immunotherapy Market, By Therapy Type, By Source, By Indication, By Manufacturing Modality, By End User, By Geography

出版日期: 2025年08月19日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

細胞免疫療法市場規模預計在 2025 年達到 76.4 億美元，預計到 2032 年將達到 204.5 億美元，2025 年至 2032 年的複合年成長率為 15.1%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	76.4億美元
效能數據	2020年至2024年	預測期	2020年至2024年
預測期：2025-2032年複合年成長率：	15.10%	2032年的價值預測	204.5億美元

全球細胞免疫療法市場代表了現代醫學的革命性模式轉移，利用人體免疫系統對抗各種疾病，特別是癌症和自體免疫疾病。

這些創新治療方法涉及提取、改造和重新註入患者免疫細胞，以增強自然防禦機制。細胞免疫療法包括多種治療方法，包括 CAR-T 細胞療法、腫瘤浸潤淋巴細胞 (TIL) 療法、自然殺手 (NK) 細胞療法和樹突狀細胞疫苗，每種療法都提供針對特定疾病途徑的獨特作用機制。

隨著Kymriah和Yescarta等CAR-T療法獲得里程碑式的核准，並在治療難治性骨髓惡性腫瘤方面顯示出顯著的療效，市場正經歷著前所未有的成長。自動化細胞處理系統和封閉式生物反應器等先進的製造技術顯著提高了這些個人化療法的擴充性和標準化程度。

包括 CRISPR-Cas9 等基因編輯工具、合成生物學平台以及人工智慧驅動的患者選擇演算法在內的生物技術創新的融合，持續拓展細胞免疫療法的治療潛力。隨著全球醫療保健體系逐漸認知到這些活體藥物的變革潛力，對研究基礎設施、法規結構和報銷政策的大量投資正在加速市場採用，並使其能夠更好地服務不同的患者群體。

市場動態

全球細胞免疫療法市場正經歷強勁成長，這主要得益於多種引人注目的因素，其中最主要的是全球癌症發病率的不斷上升，尤其是骨髓惡性腫瘤，而細胞免疫療法已在這些領域展現出卓越的臨床療效。大型製藥公司、生物技術公司和學術機構對研發活動的大力投入，為細胞免疫療法市場帶來了顯著的效益，這些投入正在推動下一代細胞工程技術的創新，並將治療應用從腫瘤學擴展到自體免疫疾病、感染疾病和再生醫學領域。

監管核准途徑、突破性療法認定以及細胞免疫療法的孤兒藥認定正在加速有前景的治療方法的上市時間，並鼓勵持續的投資和開發。

然而，該市場面臨著許多限制因素，包括個人化細胞處理相關的極高製造成本、需要專業設施和訓練有素的人員的複雜供應鏈物流，以及在維持產品品質和一致性的同時擴大生產規模的技術挑戰。生產週期長，通常需要數週時間才能生產出特異性患者的治療方法，這帶來了額外的營運挑戰，並限制了重症患者的治療機會。

此外，某些細胞免疫療法相關的嚴重不利事件，例如細胞激素釋放症候群和神經毒性，需要專門的醫療基礎設施和專業知識，這限制了其在資源匱乏的醫療機構中的應用。儘管存在這些挑戰，但該市場仍提供了巨大的商業機會，具體表現在：將適應症擴展至固體癌瘤（實體瘤的患者群體遠大於目前的血液病適應症）；以及開發可大幅降低成本和生產複雜性的現成同種異體細胞療法，使治療在全球市場上更易於獲得且擴充性。

本次調查的主要特點

本報告對全球細胞免疫療法市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數概述了全球細胞免疫療法市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球細胞免疫療法市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過用於分析全球細胞免疫療法市場的各種策略矩陣，相關人員將更容易做出決策。

Novartis AG
Gilead Sciences Inc（Kite Pharma）
Bristol Myers Squibb Company
Johnson and Johnson（Janssen Biotech）
Cellectis SA
Adaptimmune Therapeutics plc
Autolus Therapeutics plc
Allogene Therapeutics Inc
Atara Biotherapeutics Inc
Legend Biotech Corporation
bluebird bio Inc
Fate Therapeutics Inc
ImmunityBio Inc
Iovance Biotherapeutics Inc
Poseida Therapeutics Inc

第 11 章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8447

Cellular Immunotherapy Market is estimated to be valued at USD 7.64 Bn in 2025 and is expected to reach USD 20.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.64 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2020 To 2024
Forecast Period 2025 to 2032 CAGR:	15.10%	2032 Value Projection:	USD 20.45 Bn

The global cellular immunotherapy market represents a revolutionary paradigm shift in modern medicine, leveraging the body's own immune system to combat various diseases, particularly cancer and autoimmune disorders.

This innovative therapeutic approach involves extracting, modifying, and reintroducing immune cells back into patients to enhance their natural defense mechanisms. Cellular immunotherapy encompasses diverse treatment modalities including CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, natural killer (NK) cell therapy, and dendritic cell vaccines, each offering unique mechanisms of action to target specific disease pathways.

The market has witnessed unprecedented growth following breakthrough approvals of CAR-T therapies such as Kymriah and Yescarta, which demonstrated remarkable efficacy in treating refractory hematologic malignancies. Advanced manufacturing technologies, including automated cell processing systems and closed-system bioreactors, have significantly improved the scalability and standardization of these personalized treatments.

The convergence of biotechnology innovations, including gene editing tools like CRISPR-Cas9, synthetic biology platforms, and artificial intelligence-driven patient selection algorithms, continues to expand the therapeutic potential of cellular immunotherapies. As healthcare systems globally recognize the transformative potential of these living medicines, substantial investments in research infrastructure, regulatory frameworks, and reimbursement policies are accelerating market adoption and accessibility across diverse patient populations.

Market Dynamics

The global cellular immunotherapy market experiences robust growth driven by several compelling factors, with the primary driver being the increasing prevalence of cancer worldwide, particularly hematologic malignancies where cellular immunotherapies have demonstrated exceptional clinical outcomes. The market benefits significantly from substantial investments in research and development activities by pharmaceutical giants, biotechnology companies, and academic institutions, fostering innovation in next-generation cell engineering technologies and expanding therapeutic applications beyond oncology into autoimmune diseases, infectious diseases, and regenerative medicine.

Regulatory agencies' establishment of expedited approval pathways, breakthrough therapy designations, and orphan drug status for cellular immunotherapies has accelerated time-to-market for promising treatments, encouraging continued investment and development.

However, the market faces considerable restraints including extremely high manufacturing costs associated with personalized cell processing, complex supply chain logistics requiring specialized facilities and trained personnel, and significant technical challenges in scaling production while maintaining product quality and consistency. Lengthy manufacturing timelines, often requiring weeks to produce patient-specific treatments, pose additional operational challenges and limit treatment accessibility for critically ill patients.

Furthermore, severe adverse events such as cytokine release syndrome and neurotoxicity associated with certain cellular immunotherapies necessitate specialized medical infrastructure and expertise, constraining adoption in healthcare facilities lacking adequate resources. Despite these challenges, the market presents substantial opportunities through expanding applications into solid tumors, which represent a significantly larger patient population than current hematologic indications, and the development of off-the-shelf allogeneic cell therapies that could dramatically reduce costs and manufacturing complexity while improving treatment accessibility and scalability across global markets.

Key Features of the Study

This report provides in-depth analysis of the global cellular immunotherapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cellular immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Gilead Sciences Inc (Kite Pharma), Bristol Myers Squibb Company, Johnson and Johnson (Janssen Biotech), Cellectis S.A., Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Allogene Therapeutics Inc, Atara Biotherapeutics Inc, Legend Biotech Corporation, bluebird bio Inc, Fate Therapeutics Inc, ImmunityBio Inc, Iovance Biotherapeutics Inc, and Poseida Therapeutics Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cellular immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cellular immunotherapy market

Market Segmentation

Therapy Type Insights (Revenue, USD Bn, 2020 - 2032)
- CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- TCR-T Cell Therapy (T-Cell Receptor T-cell)
- NK Cell Therapy (Natural Killer cell therapy)
- Dendritic Cell Therapy
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Macrophage-Based Cell Therapy
- Others (emerging/novel cell types)
Source Insights (Revenue, USD Bn, 2020 - 2032)
- Autologous (patient-derived cells)
- Allogeneic (donor-derived cells)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Cancer
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
- Infectious Diseases
- Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
- Bacterial Infections (e.g., tuberculosis)
- Autoimmune Disorders
- Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
- Others
Manufacturing Modality Insights (Revenue, USD Bn, 2020 - 2032)
- Ex Vivo Cell Expansion
- In Vivo Engineering
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Endocrinology and Obesity Centers
- Ambulatory Surgical Centers (ASCs)
- Home Healthcare Services
- Others (Academic and Research Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis AG
- Gilead Sciences Inc (Kite Pharma)
- Bristol Myers Squibb Company
- Johnson and Johnson (Janssen Biotech)
- Cellectis S.A.
- Adaptimmune Therapeutics plc
- Autolus Therapeutics plc
- Allogene Therapeutics Inc
- Atara Biotherapeutics Inc
- Legend Biotech Corporation
- bluebird bio Inc
- Fate Therapeutics Inc
- ImmunityBio Inc
- Iovance Biotherapeutics Inc
- Poseida Therapeutics Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Cellular Immunotherapy Market, By Therapy Type
- Global Cellular Immunotherapy Market, By Source
- Global Cellular Immunotherapy Market, By Indication
- Global Cellular Immunotherapy Market, By Manufacturing Modality
- Global Cellular Immunotherapy Market, By End User
- Global Cellular Immunotherapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Cellular Immunotherapy Market, By Therapy Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
TCR-T Cell Therapy (T-Cell Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
NK Cell Therapy (Natural Killer cell therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Dendritic Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Macrophage-Based Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (emerging/novel cell types)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Cellular Immunotherapy Market, By Source, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Autologous (patient-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Allogeneic (donor-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cellular Immunotherapy Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
- Bacterial Infections (e.g., tuberculosis)
Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cellular Immunotherapy Market, By Manufacturing Modality, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Ex Vivo Cell Expansion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
In Vivo Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cellular Immunotherapy Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Endocrinology and Obesity Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Home Healthcare Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Cellular Immunotherapy Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences Inc (Kite Pharma)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson and Johnson (Janssen Biotech)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cellectis S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Adaptimmune Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Autolus Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allogene Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Atara Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Legend Biotech Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
bluebird bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fate Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
ImmunityBio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Iovance Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Poseida Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies